Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Sarepta Therapeutics will pay $60 million up front for access to five gene-therapy candidates under development by Myonexus Therapeutics to treat specific forms of muscular dystrophy. Sarepta made a name for itself in treating muscular dystrophy after U.S. FDA approval of its drug eteplirsen in 2016. Myonexus, a spin-off from Nationwide Children’s Hospital in Columbus, Ohio, just raised its first $2.5 million in seed funding in December. The new firm could earn up to $45 million in additional milestone payments in the deal with Sarepta.
This article has been sent to the following recipient: